EQS-Adhoc

Kuros Biosciences Ltd. appoints Chief Medical Officer

EQS Group-Ad-hoc: Kuros Biosciences AG / Key word(s): Change of Personnel
Kuros Biosciences Ltd. appoints Chief Medical Officer

08.03.2016 / 07:00
Release of an ad hoc announcement pursuant to Art. 53 KR.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Schlieren (Zurich), Switzerland, March 8, 2016 - Kuros Biosciences Ltd.
("Kuros" or the "Company"), announced today that Dr. Virginia Jamieson has
been appointed Chief Medical Officer and member of the Executive Board with
immediate effect.

Dr. Jamieson has spent over 25 years in the pharmaceutical industry and has
considerable experience in early and late stage clinical development,
product registration and medical affairs. Dr. Jamieson received her medical
degree at Edinburgh University and obtained a postgraduate fellowship in
anesthesia from the Royal College of Surgeons in London. In addition, she
has a diploma from the Faculty of Pharmaceutical Medicine where she has
also been an appraiser for revalidation of physicians in the pharmaceutical
industry. Dr. Jamieson already worked for Kuros from 2005 to 2012 as
Medical Director and then as Chief Medical Officer and is therefore very
familiar with Kuros' products.

Didier Cowling, CEO of Kuros, said: "We are delighted to have Virginia join
us again. Her wealth of experience, both in the surgical field and
pharmaceutical and medical industry, coupled with her deep knowledge of
Kuros' products, makes this a key appointment for us."

For further information, please contact:

Kuros Biosciences Ltd
Harry Welten, MBA
Chief Financial Officer
Tel: [phone]
[e-mail]

About Kuros Biosciences Ltd

Kuros Biosciences Ltd is focused on the development of innovative products
for tissue repair and regeneration and is located in Schlieren (Zurich),
Switzerland. The Company is listed according to the Main Standard on the
SIX Swiss Exchange Ltd under the symbol KURN.

Forward Looking Statements
This media release contains certain forward-looking statements that involve
risks and uncertainties that could cause actual results to be materially
different from historical results or from any future results expressed or
implied by such forward-looking statements. You are urged to consider
statements that include the words "will" or "expect" or the negative of
those words or other similar words to be uncertain and forward-looking.
Factors that may cause actual results to differ materially from any future
results expressed or implied by any forward-looking statements include
scientific, business, economic and financial factors, Against the
background of these uncertainties, readers should not rely on
forward-looking statements. The Company assumes no responsibility for
updating forward-looking statements or adapting them to future events or
developments.

www.kuros.ch

End of ad hoc announcement

+++++
Additional features:

Document: http://n.eqs.com/c/fncls.ssp?u=CXTXQEOIJL
Document title: Kuros_CMO_160308

---------------------------------------------------------------------------

08.03.2016 News transmitted by EQS Schweiz AG. www.eqs.com - news archive:
http://switzerland.eqs.com/de/News

The issuer is responsible for the contents of the release.

---------------------------------------------------------------------------


Language: English
Company: Kuros Biosciences AG
Wagistrasse 25
8952 Schlieren
Switzerland
Phone: [phone]
Fax: [phone]
E-mail: [e-mail]
Internet: www.kuros.ch
ISIN: CH0011025217
Valor: -
Listed: Foreign Exchange(s) SIX


End of News EQS Group News Service
---------------------------------------------------------------------------

443197 08.03.2016